Clinical Trial Update: An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bortezomib and rituximab for relapsed or refractory follicular lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen-Cilag G.m.b.H | Conditions: Lymphoma, Follicular | Phase 2 | Status: TERMINATED